Regeneron Pharmaceuticals Inc

REGN 
(NASDAQ) 
 
$ 418.62
Updated 09:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 261,567
High $ 422.61
Low $ 415.59
Open $ 421.81
ISIN
Prev close $ 422.51
# of shares 107.37M
Market cap 44,945M USD
Intraday

Market closed
Regeneron Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  418.62 -1.3% Stock price decreasing 3.4% Stock price increasing 22.0% Stock price increasing 10.1% Stock price increasing 32.6% Stock price increasing
Powered by TradingView

News about Regeneron Pharmaceuticals Inc

  • English
  • Regulatory news
12 Feb
 
17 Jan
 
03 Dec
 
24 Oct
 
31 Aug
 
27 Jul
 
22 Feb
 

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:16:36
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB4 - 2019-02-22 10:16:36 - 2019-02-22 09:16:36 - 1000 - Website: OKAY